Literature DB >> 19181743

Heterogenous spectrum of CFTR gene mutations in Indian patients with congenital absence of vas deferens.

N Sharma1, N Acharya, S K Singh, M Singh, U Sharma, R Prasad.   

Abstract

BACKGROUND: Mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene can cause congenital bilateral absence of vas deferens. Yet, the spectrum and frequency of CFTR mutations in Indian males with congenital absence of vas deferens (CAVD) is unknown.
METHODS: We investigated 50 Indian males, diagnosed with unilateral or bilateral absence of vas deferens at the PGIMER, Chandigarh, for the presence of the most common CFTR gene mutations as well as unknown mutations by single-strand conformation polymorphism followed by sequence analysis.
RESULTS: This study led to the identification of 12 CFTR gene mutations on 48% of 100 Indian CAVD chromosomes. CFTR mutations were identified on both alleles in 11 patients (22%) and on one allele in 26 patients (52%). Novel CFTR mutations identified were L69H, F87I, G126S, F157C, E543A, Y852F and D1270E. The T5 allele (25%) and F508del (11%) were the most common mutations identified. The most common intragenic marker haplotype for F508del was 2111 (GATT, TUB9, M470V and T854T). No mutations could be detected in 13 CAVD patients (26%), including 4 with renal malformations.
CONCLUSIONS: This study confirms the molecular heterogeneity of CFTR mutations in CAVD. Although the mutation detection rate is indeed lower in Indian CAVD patients, 74% of the patients tested had at least one CFTR mutation. CAVD alleles with no mutations suggest that other changes may be located at the non-screened sites that require extensive search by direct sequencing. Furthermore, the novel CFTR mutations identified require functional studies in a cell-based system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19181743     DOI: 10.1093/humrep/den500

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Molecular basis of cystic fibrosis disease: an Indian perspective.

Authors:  R Prasad; H Sharma; G Kaur
Journal:  Indian J Clin Biochem       Date:  2010-11-19

2.  New Perspectives in Underlying Molecular Defects Based Cystic Fibrosis Therapeutics.

Authors:  Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2021-06-15

3.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene abnormalities in Indian males with congenital bilateral absence of vas deferens & renal anomalies.

Authors:  Rahul Gajbhiye; Kaushiki Kadam; Aalok Khole; Avinash Gaikwad; Seema Kadam; Rupin Shah; Rangaswamy Kumaraswamy; Vrinda Khole
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

4.  CFTR variants and renal abnormalities in males with congenital unilateral absence of the vas deferens (CUAVD): a systematic review and meta-analysis of observational studies.

Authors:  Hongcai Cai; Xingrong Qing; Jean Damascene Niringiyumukiza; Xuxin Zhan; Dunsheng Mo; Yuanzhong Zhou; Xuejun Shang
Journal:  Genet Med       Date:  2018-09-14       Impact factor: 8.822

5.  CFTR gene variants in Indian congenital bilateral absence of vas deferens & its relevance in genetic counselling.

Authors:  Ashutosh Halder; Deepak Pandey
Journal:  Indian J Med Res       Date:  2020-12       Impact factor: 2.375

6.  Cystic fibrosis transmembrane conductance regulator-related male infertility: Relevance of genetic testing & counselling in Indian population.

Authors:  Avinash Gaikwad; Shagufta Khan; Seema Kadam; Rupin Shah; Vijay Kulkarni; Rangaswamy Kumaraswamy; Kaushiki Kadam; Vikas Dighe; Rahul Gajbhiye
Journal:  Indian J Med Res       Date:  2020-12       Impact factor: 2.375

7.  Data on the functional consequences of the mutations identified in 21-Hydroxylase deficient CAH patients.

Authors:  Ragini Khajuria; Rama Walia; Anil Bhansali; Rajendra Prasad
Journal:  Data Brief       Date:  2018-05-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.